Drugs / ALS20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06364774 | Apr 2025 → Dec 2027 expected | beta thalassemia | Children's Hospital of Philadelphia | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALS20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06364774 ↗ |
| Known as | CHOP-ALS20 | “The gene modified blood stem cells are called CHOP-ALS20 ("study drug").” NCT06364774 ↗ |